NielsenIQ (NIQ) appoints Steen Lomholt-Thomsen as Chief Commercial Officer
NIQ, the world’s leading consumer intelligence company, announced the appointment of Steen Lomholt-Thomsen as its new Chief Commercial Officer, effective November 1, 2024. Steen will drive client strategy and enhance global growth as NielsenIQ expands its capabilities to deliver mission-critical insights into the most holistic view of consumer shopping behavior. NIQ’s AI capabilities, together with its core data assets and unmatched global footprint, are uniquely positioned to give clients the Full View™: a holistic view of shopper behavior.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101505660/en/
Steen Lomholt-Thomsen NIQ Chief Commercial Officer (Photo: Business Wire)
Steen brings extensive experience leading revenue growth and operational excellence in complex global organizations, including BullWall, Clarivate, and Aveva, and has held leadership roles in companies including IBM, HP, and IHS (now S&P Global). He brings a deep understanding of global markets, client engagement, software, and technology, and will further NIQ’s mission of empowering businesses to make the right strategic decisions.
“NIQ operates in more than 90 countries globally. Steen is a proven leader with a track record of success across industries,” said Tracey Massey, NIQ’s Chief Operating Officer. “His experience in operational excellence and building client relationships makes him a perfect fit to advance our strategic goals.”
“I am incredibly excited to join NIQ and help deliver the industry’s most advanced consumer insights and analytics to the market,” said Lomholt-Thomsen. “I’m equally looking forward to partnering with our fantastic clients and helping them reach new heights as we further harness the power of NIQ’s data and capabilities.”
Steen will be based in NIQ’s Geneva, Switzerland office.
About NIQ
NielsenIQ (NIQ) is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in more than 95 countries covering 97% of GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.
For more information, please visit www.niq.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101505660/en/
Contacts
Media:
Sweta Patra
swetapatra@nielseniq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision5.11.2024 00:18:00 EET | Press release
LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the U.S. Food & Drug Administration (FDA) has authorized marketing of Valeda® Light Delivery System for treatment of patients with dry age-related macular degeneration (AMD), a leading cause of central vision loss in people over 55 in developed countries. The Valeda therapy is the first ever authorized treatment by the FDA for vision loss in dry AMD patients. Valeda provides an improvement in best corrected visual acuity (BCVA) over 24 months of >5 letters or equivalent to a line on the eye chart. In the pivotal U.S. LIGHTSITE III trial, the Valeda treatment met its primary endpoint and was shown to be safe and effective in increasing and maintaining improved visual acuity. LumiThera submitted the US LIGHTSITE III clinical data as part of a technical package to the FDA under a De Novo request with special controls. “The De Novo authorization established Va
Westinghouse Signs Contract for Engineering of AP1000 ® Reactors in Bulgaria4.11.2024 22:12:00 EET | Press release
Westinghouse Electric Company, Hyundai Engineering & Construction Co. and Bulgaria’s Kozloduy NPP - New Build EAD today signed the Engineering Services Contract for two AP1000® reactors to be built at the Kozloduy site. Bulgarian Prime Minister Dimitar Glavchev, Bulgarian Minister of Energy Vladimir Malinov, U.S. Ambassador to Bulgaria Kenneth Merten, Executive Director of Kozloduy NPP - New Build Petyo Ivanov, Senior Vice President of Westinghouse Energy Systems Elias Gedeon, and Hyundai Engineering & Construction President and CEO Yoon Young-Joon attended the signing ceremony in Sofia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104293861/en/ Following the signing ceremony. From left: Yoon Young-Joon, President and CEO, Hyundai Engineering & Construction; Ji I Cho, Deputy Head of Mission and Charge d'Affaires a.i., Embassy of the Republic of Korea; Vladimir Malinov, Minister of Energy, Bulgaria; Dimitar Glavchev, Pri
Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings4.11.2024 21:50:00 EET | Press release
ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized pharmacovigilance (PV) expert Shelley Gandhi has joined the firm. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline compliance, manage risk, and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104361511/en/ Shelley Gandhi joins ELIQUENT Life Sciences - bolsters expanded Pharmacovigilance & Risk Management Solutions (Photo: Business Wire) “Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex regulatory challenges will be instrumental in expanding ELIQUENT’s pharmacovigilance solutions to meet the growing global demand for comprehensive safety and risk management across diverse markets,” said Tim Dietlin, Chief Executiv
Earnix Survey Reveals Majority of Insurers Plan to Implement AI Predictive Models Within Two Years4.11.2024 18:10:00 EET | Press release
Earnix, the leading AI, real-time platform for intelligent decisioning SaaS solutions for the insurance and financial services industries, today announced its third annual survey on the state of the insurance market, the 2024 Industry Trends Report. The survey of over 400 global insurance executives uncovers key findings, trends, implications for what’s next in insurance, and sheds light on the role technology can play in shaping a better future. Key findings from the 2024 survey include: More than two-thirds (70%) of respondents expect to deploy AI models that make predictions based on real-time data in the next two years More than half of respondents (51%) report their company had to pay a fine or issue refunds due to errors in the last year 58% of respondents take more than 5 months to implement a rule change and 21% take longer than 7 months Insurers still need to move beyond legacy systems and fully modernize their operations, yet 49% admit they are behind schedule “This year’s su
Parse Biosciences Launches Evercode Low Input Fixation for Cells and Nuclei4.11.2024 18:00:00 EET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch and availability of Evercode™ Low Input Fixation kits for both cells and nuclei. The new kits empower researchers who have a small number of starting cells or nuclei who ordinarily might not be able to perform single cell sequencing using fixed cells. Fixation is a strategy used by many single cell researchers because it enables them to collect samples at different times and then perform library preparation and sequencing at once when all of the samples are amassed. Yet, a well-known challenge across all fixation technologies is that they require a certain number of cells or nuclei, usually 50,000 or greater. With the new kits from Parse, researchers can start with as few as 10,000 cells or nuclei. The new low input fixation kits are ideal for researchers working with limited cells across various conditions or those handling rare and precious samples. These kits
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom